Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardio Diagnostics Holdings (CDIO) EBITDA (2021 - 2025)

Cardio Diagnostics Holdings' EBITDA history spans 5 years, with the latest figure at -$1.7 million for Q3 2025.

  • For Q3 2025, EBITDA fell 21.48% year-over-year to -$1.7 million; the TTM value through Sep 2025 reached -$6.5 million, up 22.1%, while the annual FY2024 figure was -$8.4 million, 15.51% down from the prior year.
  • EBITDA for Q3 2025 was -$1.7 million at Cardio Diagnostics Holdings, down from -$1.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$397.0 in Q2 2021 and bottomed at -$4.2 million in Q1 2024.
  • The 5-year median for EBITDA is -$1.5 million (2023), against an average of -$1.5 million.
  • The largest annual shift saw EBITDA crashed 198127.71% in 2022 before it surged 60.79% in 2025.
  • A 5-year view of EBITDA shows it stood at -$145321.0 in 2021, then crashed by 2416.83% to -$3.7 million in 2022, then surged by 57.84% to -$1.5 million in 2023, then grew by 1.66% to -$1.5 million in 2024, then dropped by 12.87% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for CDIO's EBITDA are -$1.7 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.6 million (Q1 2025).